Complete Genomics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of shares of its common stock. The shares of common stock to be sold in this offering are proposed to be sold solely by Complete Genomics, Inc.
UBS Investment Bank and Jefferies & Company will be acting as joint book-running managers, with Baird and Cowen and Company acting as co-managers for the offering. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from the prospectus department of UBS Investment Bank at 299 Park Avenue, New York, NY 10171, Attention: Prospectus Department, or via telephone at (888) 827-7275, or from the prospectus department of Jefferies & Company at 520 Madison Avenue, New York, NY 10022, Attention: Syndicate Prospectus Department, or via telephone at (888) 449-2342.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall neither constitute an offer to sell nor a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Complete Genomics
Complete Genomics is a life sciences company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA Platform) combines Complete Genomics’ proprietary human genome sequencing technology with our advanced informatics and data management software. We offer this solution as an innovative, end-to-end, outsourced service and provide customers with data that is immediately ready to be used for genome-based research.
Investor Relations
Scott Sandler, 650-943-2788
ssandler@completegenomics.com
or
Complete Genomics, Inc.
Vice President of Marketing
Jennifer Turcotte, 650-943-2846
jturcotte@completegenomics.com
|
